E-ISSN 2218-6050 | ISSN 2226-4485
 

Case Report


Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis

Eleanor Marie Kellon, Kathleen M Gustafson.


Cited By:13

Abstract
Ten laminitic horses with hyperinsulinemia refractory to diet control, metformin, levothyroxine and pergolide (if diagnosed with PPID) were treated with the sodium-glucose cotransporter-2 inhibitor canagliflozin (Invokana®). Nine horses were hyperglycemic (>5.5 mmol/L) or had a history of hyperglycemia. Prior to instituting therapy, renal function was assessed by determining serum creatinine and blood urea nitrogen concentrations. Canagliflozin was administered orally once a day, with food. Dipstick urinalysis was performed every 2 wk to confirm glucosuria and screen for proteinuria. Owners were also instructed regarding clinical signs consistent with urinary tract infection. All horses responded with a substantial decrease in serum insulin concentrations to normal or near normal values. Laminitis pain resolved in all cases, with regression of fat deposits. Owner satisfaction with outcomes was 100%.

Key words: horses refractory hyperinsulinemia laminitis canagliflozin


 
ARTICLE TOOLS
Abstract
PDF Fulltext
HTML Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Eleanor Marie Kellon
Articles by Kathleen M Gustafson
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Kellon EM, Gustafson KM. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Vet J. 2022; 12(4): 511-518. doi:10.5455/OVJ.2022.v12.i4.14


Web Style

Kellon EM, Gustafson KM. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. https://www.openveterinaryjournal.com/?mno=103770 [Access: June 03, 2024]. doi:10.5455/OVJ.2022.v12.i4.14


AMA (American Medical Association) Style

Kellon EM, Gustafson KM. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Vet J. 2022; 12(4): 511-518. doi:10.5455/OVJ.2022.v12.i4.14



Vancouver/ICMJE Style

Kellon EM, Gustafson KM. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Vet J. (2022), [cited June 03, 2024]; 12(4): 511-518. doi:10.5455/OVJ.2022.v12.i4.14



Harvard Style

Kellon, E. M. & Gustafson, . K. M. (2022) Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Vet J, 12 (4), 511-518. doi:10.5455/OVJ.2022.v12.i4.14



Turabian Style

Kellon, Eleanor Marie, and Kathleen M Gustafson. 2022. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Veterinary Journal, 12 (4), 511-518. doi:10.5455/OVJ.2022.v12.i4.14



Chicago Style

Kellon, Eleanor Marie, and Kathleen M Gustafson. "Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis." Open Veterinary Journal 12 (2022), 511-518. doi:10.5455/OVJ.2022.v12.i4.14



MLA (The Modern Language Association) Style

Kellon, Eleanor Marie, and Kathleen M Gustafson. "Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis." Open Veterinary Journal 12.4 (2022), 511-518. Print. doi:10.5455/OVJ.2022.v12.i4.14



APA (American Psychological Association) Style

Kellon, E. M. & Gustafson, . K. M. (2022) Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Veterinary Journal, 12 (4), 511-518. doi:10.5455/OVJ.2022.v12.i4.14